Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03786770 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)
A Phase 2 study, sponsored by Revance Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT03786770 is a Phase 2 study that has completed, run by Revance Therapeutics. The registered enrollment target is 61 participants.
The verdict
NCT03786770, a Phase 2 study, has completed, sponsored by Revance Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
This is a phase 2a, multicenter, open-label, dose-escalation study to evaluate treatment of moderate or severe dynamic forehead lines (FHL) (frontalis) in conjunction with treatment of the glabellar complex.
Interventions
- BIOLOGICAL DaxibotulinumtoxinA for injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2019-01-24 |
| Est. Completion | 2020-03-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03786770
The ClinicalTrials.gov registry entry for NCT03786770 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Revance Therapeutics, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DaxibotulinumtoxinA for injection is the first listed.
NCT03786770 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03786770 about?
NCT03786770 is a clinical study titled "Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)". This is a phase 2a, multicenter, open-label, dose-escalation study to evaluate treatment of moderate or severe dynamic forehead lines (FHL) (frontalis) in conjunction with treatment of the glabellar complex.
What is the current status of trial NCT03786770?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2019-01-24. Estimated completion is 2020-03-09.
What interventions are being tested in trial NCT03786770?
The interventions under investigation include: DaxibotulinumtoxinA for injection (BIOLOGICAL).
Who is sponsoring clinical trial NCT03786770?
This trial is sponsored by Revance Therapeutics, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.